Technical Articles

Once defined by lactation biology, the prolactin receptor PRLR has re-entered targeted research three decades later on the strength of high expression profiles in luminal breast cancer. This article unpacks the receptor's dual identity and translatio

A systematic review of the prolactin receptor (PRLR), a class I cytokine receptor family member that transmits prolactin signals via the JAK2-STAT5 pathway: receptor structure and isoforms, signaling hierarchy, physiological functions, and the toolki

BRD4, short for Bromodomain-containing protein 4, belongs to the BET protein family. The BET family comprises four proteins, namely BRD2, BRD3, BRD4, and BRDT, which share a conserved modular structure consisting of two N-terminal tandem BRD effector domains and an additional C-terminal motif.

The discovery of CCL25 represents an important milestone in cancer research. It not only helps us better understand the mechanism of breast cancer metastasis, but also provides a direction for developing new treatment strategies.

Human epidermal growth factor receptor 2 (HER2) is a key marker for molecular typing of breast cancer. Accurate evaluation of its expression level plays a decisive role in treatment decisions. With the release of milestone studies such as DESTINY-Break04, the clinical value of HER2 low expression (IHC 1+or 2+/ISH -) breast cancer is increasingly prominent.